You are here

Penicillin Misconceptions May Lead to Surgical Infections

When patients wrongly report drug allergies, doctors use inferior drugs, study finds

Surgical patients who report having a penicillin allergy face a 50% higher risk for a postoperative infection compared with patients who report no drug allergy, a new study finds. Researchers from Massachusetts General Hospital attributed the higher surgical-site infection rate to the use of alternative antibiotics.

Because many people erroneously believe they’re allergic to penicillin, the findings suggest this common misconception may put some patients in harm’s way.

“This study has direct clinical significance,” said study lead author Kimberly Blumenthal, MD, who is in the division of rheumatology, allergy, and immunology. “We already know that more than 95% of patients who believe they have penicillin allergy can actually tolerate the drug.”

The study results indicate that a preoperative penicillin evaluation could effectively reduce surgical site infections in these patients, Blumenthal said in a hospital news release. Four in 10 hospital infections occur at surgical incision sites, the researchers noted. Such infections can sometimes lead to serious complications and even death.

The researchers analyzed the medical records of 8,400 patients who underwent surgery between 2010 and 2014 for issues such as hip or knee replacement, hysterectomy, colon surgery, and heart bypass. More than 900 had an allergy to penicillin noted in their medical records prior to surgery.

More than 200 patients ended up with some type of surgical site infection, the study team found. That included 2.6% with no known allergy to penicillin and 3.5% of patients who believed they were allergic to the drug and therefore didn’t receive it.

Based on the findings, the study team said prospective surgical patients who believe they are allergic to penicillin should undergo a fresh allergy evaluation in advance of their operation.

The findings appear in the October 9 online issue of Clinical Infectious Diseases.

Source: HealthDay News; October 9, 2017.

More Headlines

Manufacturer used FDA’s 505(b)(2) abbreviated approval pathway
This is the first drug for patients with eosinophilic granulomatosis with polyangiitis
Industry will provide funding for programs in partnership with Addiction Policy Forum
Platform offers advanced technology to treat symptoms of Parkinson’s disease
Four in 10 remain in complete remission, updated data show
Patients with high PD-L1 level show benefit in first-line treatment
Pfizer launches generic to counteract Teva’s version
Tecentriq was combined with Avastin and chemotherapy as initial treatment